ClinicalTrials.Veeva

Menu

Incidence of Myopia in a Prospective Cohort of Emmetropic Children and Associated Ocular and Environmental Factors (PREMYOP)

F

Fondation Ophtalmologique Adolphe de Rothschild

Status

Not yet enrolling

Conditions

Myopia

Treatments

Other: annual follow-up

Study type

Observational

Funder types

NETWORK

Identifiers

NCT07316998
TCN_2025_8

Details and patient eligibility

About

Myopia and high myopia are among the leading causes of visual impairment and blindness worldwide. The total number of people with myopia worldwide was estimated at 2.6 billion in 2020 and could reach 4.8 billion by 2050 unless preventive interventions are implemented.

Most epidemiological studies have focused on risk factors for myopia progression, with far fewer addressing the factors that cause a child to shift from emmetropia to myopia. The risk factors for the onset of myopia may be the same as those for myopia progression. However, for an equivalent level of risk exposure, it remains unclear why some children develop myopia while others do not.

Identifying the population most at risk of developing myopia would make it possible to propose preventive treatments aimed at delaying or preventing its onset. This would allow evaluation of the effectiveness of current myopia control treatments (peripheral defocus lenses, atropine, contact lenses) in preventing the onset of myopia, as well as future targeted treatments, including the potential benefit of early optical correction-a strategy once used but later abandoned due to a lack of robust scientific evidence.

The establishment of longitudinal follow-up of young emmetropic children at the French Institute of Myopia will enable the acquisition of high-quality imaging, allowing investigation of the association between advanced imaging parameters and external environmental factors with the onset of myopia.

Enrollment

100 estimated patients

Sex

All

Ages

4 to 8 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 4 years and < 9 years
  • Spherical equivalent measured by autorefractometer ≥ 0.00 and ≤ +2.00 diopters in each eye (cycloplegic autorefraction)

Exclusion criteria

  • Presence of trauma in at least one eye
  • Presence of inflammatory ocular pathology in at least one eye
  • History of intraocular pressure-lowering ophthalmic treatment, intravitreal injections, laser treatment, or myopia control therapy (e.g., atropine, orthokeratology, myopia control lenses)
  • History of ophthalmic surgery other than for the management of strabismus (e.g., cataract surgery, filtering surgery, intravitreal surgery) in at least one eye

Trial design

100 participants in 1 patient group

Children aged 4 to 8 years at inclusion, emmetropic (cycloplegic SE 0 to +2D) in each eye d
Treatment:
Other: annual follow-up

Trial contacts and locations

0

Loading...

Central trial contact

Yavchitz

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems